first reported a link between mutations of the TERT promoter and BRAF (V600E) in PTC, and subsequent studies further demonstrated the coexistence of TERT promoter and BRAF(V600E) mutations in thyroid cancers and their association with the most aggressive PTC clinical factors and worse prognosis (47–50). The gene discussed is BRAF; the disease is thyroid gland carcinoma.